1. Home
  2. EQV vs ABVX Comparison

EQV vs ABVX Comparison

Compare EQV & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EQV
  • ABVX
  • Stock Information
  • Founded
  • EQV 2024
  • ABVX 2013
  • Country
  • EQV United States
  • ABVX France
  • Employees
  • EQV N/A
  • ABVX N/A
  • Industry
  • EQV
  • ABVX
  • Sector
  • EQV
  • ABVX
  • Exchange
  • EQV Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • EQV 472.5M
  • ABVX 511.3M
  • IPO Year
  • EQV 2024
  • ABVX N/A
  • Fundamental
  • Price
  • EQV $10.50
  • ABVX $7.66
  • Analyst Decision
  • EQV
  • ABVX Buy
  • Analyst Count
  • EQV 0
  • ABVX 4
  • Target Price
  • EQV N/A
  • ABVX $31.50
  • AVG Volume (30 Days)
  • EQV 243.1K
  • ABVX 273.1K
  • Earning Date
  • EQV 01-01-0001
  • ABVX 08-11-2025
  • Dividend Yield
  • EQV N/A
  • ABVX N/A
  • EPS Growth
  • EQV N/A
  • ABVX N/A
  • EPS
  • EQV N/A
  • ABVX N/A
  • Revenue
  • EQV N/A
  • ABVX $11,444,012.00
  • Revenue This Year
  • EQV N/A
  • ABVX $284.20
  • Revenue Next Year
  • EQV N/A
  • ABVX N/A
  • P/E Ratio
  • EQV $51.20
  • ABVX N/A
  • Revenue Growth
  • EQV N/A
  • ABVX 128.98
  • 52 Week Low
  • EQV $9.88
  • ABVX $4.77
  • 52 Week High
  • EQV $10.74
  • ABVX $14.16
  • Technical
  • Relative Strength Index (RSI)
  • EQV N/A
  • ABVX 62.32
  • Support Level
  • EQV N/A
  • ABVX $5.69
  • Resistance Level
  • EQV N/A
  • ABVX $8.06
  • Average True Range (ATR)
  • EQV 0.00
  • ABVX 0.48
  • MACD
  • EQV 0.00
  • ABVX 0.09
  • Stochastic Oscillator
  • EQV 0.00
  • ABVX 83.12

About EQV EQV Ventures Acquisition Corp.

EQV Ventures Acquisition Corp is a blank check company.

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: